Background: Sepsis is the leading cause of lung injury in adults and can lead to acute respiratory distress syndrome (ARDS). Using a novel technique of isolated in vivo lung perfusion (IVLP), we hypothesized that normothermic IVLP will improve oxygenation and compliance in a porcine model of sepsis-induced lung injury.
ABSTRACT
Background: Sepsis is the leading cause of lung injury in adults and can lead to acute respiratory distress syndrome (ARDS). Using a novel technique of isolated in vivo lung perfusion (IVLP), we hypothesized that normothermic IVLP will improve oxygenation and compliance in a porcine model of sepsis-induced lung injury.
Methods: Mature adult swine (n ¼ 8) were administered lipopolysaccharide (LPS; 50 mg/kg over 2 hours) via the external jugular vein, followed by sternotomy and central extracorporeal membrane oxygenation (ECMO) cannulation (right atrium to ascending aorta). The left pulmonary artery (inflow) and left superior and inferior pulmonary veins (outflow) were dissected out and cannulated to deliver isolated perfusion to the left lung. After 4 hours of normothermic IVLP with Steen solution, the left lung then underwent 4 hours of reperfusion after IVLP decannulation. Airway pressures and lung-specific pulmonary vein blood gases from the right lung (LPS control) and left lung (LPS þ IVLP) of the same animal were compared.
Results: All animals demonstrated a significant reduction in the ratio of partial pressure of oxygen in arterial blood (PaO 2 )/fraction of inspired oxygen (FiO 2 ) (P/F ratio) and total lung compliance at 2 hours after the start of LPS infusion (mean, 469 AE 19.7 mm Hg vs 222.2 AE 21.4 mm Hg; P<.0001). After reperfusion, 6 animals (75%) exhibited improved lung function, allowing for ECMO decannulation. Lung-specific oxygenation was superior in the left lung after 4 hours of reperfusion (mean, 310.5 AE 54.7 mm Hg vs 201.1 AE 21.7 mm Hg; P ¼ .01). Similarly, total lung compliance improved after IVLP of the left lung. The lung wet weight to dry weight ratio demonstrated reduced edema in rehabilitated left lungs (mean, 6.5 AE 0.3 vs 7.5 AE 0.4; P ¼ .04).
Conclusions: IVLP successfully rehabilitated LPS-injured lungs compared to ECMO support alone in this preclinical porcine model. (J Thorac Cardiovasc Surg 2018;155:440-8)
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Central Message
IVLP can successfully rehabilitate LPSinduced lung injury with improved oxygenation compared to ECMO support alone in a preclinical porcine model.
Perspective
When translated into a percutaneous platform, in vivo lung perfusion may provide a reliable means to rehabilitate various types of acute lung injury in patients on ECMO to reduce the morbidity and mortality in ARDS.
See Editorial Commentary page 449.
See Editorial page 438.
Acute respiratory distress syndrome (ARDS) represents the final devastating result of acute lung injury. This condition has deleterious long-term effects on patients' quality of life and carries significant mortality. [1] [2] [3] Infection and circulatory shock are the predominant etiologies of ARDS. 2, 4 Extracorporeal membrane oxygenation (ECMO) and protective ventilation strategies are the current standards of care, yet they provide only passive support for innate mechanisms of healing that occur over an often-protracted time course.
1,2,5 Current forms of pharmacotherapy are extremely limited. Data in support of early corticosteroid use are inconclusive, and administration beyond 14 days is contraindicated. [6] [7] [8] Early treatment with a 48-hour infusion of the neuromuscular blocking agent cisatracurium has been shown to reduce mortality, but has no effect on the duration of mechanical ventilator support. [9] [10] [11] At present, there are no available methods to treat and rapidly rehabilitate lungs affected by ARDS. It has become increasingly apparent that a technological breakthrough is needed to reduce the significant mortality associated with this grave disease.
Recently, ex vivo lung perfusion (EVLP) has demonstrated clinical utility as a platform for assessing donor lungs before transplantation.
12 Work in our laboratory has shown that EVLP also may provide a useful therapeutic platform for the rehabilitation of injured lungs. [13] [14] [15] This therapy involves placement of cannulas in the pulmonary artery (PA) (inflow) and the left atrium (outflow) for perfusion and an endotracheal tube into the trachea to ventilate the lungs after excision from a donor. The EVLP circuit design is modified from clinical cardiopulmonary bypass and is used for the ex vivo perfusion of lungs. The perfusion circuit includes a membrane deoxygenator that enables evaluation of the oxygenation capacity of the donor lungs. 12, 16 The use of Steen solution (XVIVO Perfusion, Englewood, Colo), a physiological solution consisting of albumin, dextran, and electrolytes supplemented with steroids, antibiotics, and heparin, in EVLP can reduce lung edema, provide free radical scavenging, and ameliorate harmful inflammation and endothelial damage. Steen solution provides an ideal platform for targeted drug, cellular, or gene therapy during EVLP for further improvement in lung recovery. The EVLP circuit also includes a leukocyte-reducing filter, which decreases the burden of circulating inflammatory cells. Finally, a critical principle of EVLP is the maintenance of physiological back-pressure (þ1 to 5 mm Hg) on the pulmonary venous drainage to reduce cavitation and vascular injury. 16 This technology has been taken one step further for isolated lung perfusion in vivo, although it has never been used with rehabilitative intent. [17] [18] [19] ; Circulatory shock secondary to sepsis is the leading cause of ARDS. Using a porcine model of ARDS induced by endotoxin-mediated lung injury, we sought to test the rehabilitative potential of a novel strategy of isolated left lung in vivo lung perfusion (IVLP) therapy. This previously validated model of sepsis-induced ARDS using systemic lipopolysaccharide (LPS) produces a dose-dependent reduction in oxygenation and lung compliance. 20, 21 We previously demonstrated a decrease in the ratio of the partial pressure of oxygen in arterial blood (PaO 2 ) to the fraction of inspired oxygen (FiO 2 ) (P/F ratio) and a reduction of dynamic compliance over 4 hours of EVLP. 22 In the present study, we hypothesized that isolated left lung perfusion via IVLP would result in attenuation of lung injury with reduced inflammation and edema compared with lungs that received ECMO support only.
METHODS

Animals and Study Groups
The University of Virginia's Animal Care and Use Committee approved this study and ensured that all procedures were performed in compliance with the National Institutes of Health's 1996 Guide for the Care and Use of Laboratory Animals. Eight farm-raised swine of both sexes (weight, 45-50 kg) were used for this study. In each animal, after induction of general anesthesia, a right carotid artery catheter was placed for blood pressure monitoring, a left jugular vein catheter was placed for vascular access, and a Swan-Ganz catheter was placed to monitor cardiac function and blood flow. The animal remained anesthetized with pentobarbital infusion for the duration of the experiment. Conventional ventilation was used with a tidal volume of 8 mL/kg, a respiratory rate of 12 to 16 breaths/minute, a positive end-expiratory pressure of 5 mm Hg, and an FiO 2 of 0.40. Systemic arterial blood gases and lung compliance were measured every 30 minutes for the duration of the experiment to assess lung function and performance.
Lung Injury Protocol
If baseline arterial blood gas and lung compliance measurements demonstrated no intrinsic lung injury, 50 mg/kg of LPS (from Escherichia coli 0127; B8, Sigma-Aldrich, St Louis, Mo) was infused over a 2-hour period to induce lung injury. Then lidocaine (50 mg) was administered, followed by a midline sternotomy and incision of the pericardium. If arterial blood gas and lung compliance measurements confirmed lung injury, then interlocking ascending aortic and running right atrial purse-string sutures were placed with 5-0 Prolene (Ethicon, Somerville, NJ), 100 U/kg of intravenous heparin (Hospira, Lake Forest, Ill) was administered, and an 18F Bio-Medicus arterial cannula and a
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ECMO was initiated with a target mean arterial pressure of 65 mm Hg. Ventilation was continued at lung-protective settings (tidal volume, 6 mL/ kg; respiratory rate, 8 breaths/minute; positive end-expiratory pressure, 5 mm Hg; FiO 2 , 0.21). The circuit was managed by a certified perfusion specialist following specific criteria for goal-directed resuscitation to maintain a mean arterial pressure of >65 mm Hg, including fluid boluses with normal saline and the addition of epinephrine and norepinephrine. Systemic arterial blood gas values were measured every 30 minutes to titrate oxygen delivery, and sodium bicarbonate was given for metabolic acidosis, marked by pH <7.30. Hourly activated clotting time was measured, and heparin was administered to maintain this value between 250 and 350 seconds.
In Vivo Lung Perfusion
After initiation of ECMO support, perfusion to the left lung was isolated ( Figure 1 and Video 1). The left superior and inferior pulmonary veins and left PA were dissected circumferentially and snared with 0-Silk sutures and Rommel tourniquets. Purse string sutures were placed in the left PA, the left inferior pulmonary vein, and the left atrium (for the superior vein) with a 5-0 Prolene to allow for cannulation. Arterial catheters (14F) were used for the PA and superior vein, and a 14F right-angle cannula was used for the inferior vein. After placement of each cannula, a Rommel tourniquet was used to tighten the purse string suture, and the snare suture was then cinched tight around the distal tip of the catheter to isolate each vessel. To prevent lung injury from outflow obstruction, the PA was cannulated and isolated first, followed by the inferior vein and then the superior vein. After the system was deaired, the circuit was completed with an Affinity Pixie oxygenation system (Medtronic), to deoxygenate the perfusate, and a centrifugal pump (Medtronic). Outflow was opened, followed immediately by gentle inflow, which was gradually increased to up to 8% of cardiac output with Steen solution supplemented with cefazolin (500 mg; APP Pharmaceuticals, Schaumburg, Ill), methylprednisolone (500 mg; Pfizer, New York, NY), and heparin (5000 IU) at 37.5 C. Isolated left lung perfusion (IVLP) was maintained for 4 hours while the animal was receiving on central ECMO support. Inflow (left PA) and outflow (left pulmonary vein) pressures were measured, and outflow pressure was maintained between 0 and -5 mm Hg. Lung oxygenation capacity was calculated hourly. For the right lung, the difference between the right pulmonary vein PaO 2 and right PA sample from the Swan-Ganz catheter was used. The oxygenation capacity of the left lung was calculated as the difference between IVLP circuit outflow (left pulmonary veins) and IVLP circuit inflow (left PA). Serum albumin levels were measured in the animal, in the perfusate before initiation of IVLP, and in the animal after IVLP to determine the extent of mixing between the circuits through the left bronchial arteries and left pulmonary veins. We found decreased serum albumin levels during IVLP despite very high levels of albumin in the perfusate, indicating no mixing from the IVLP circuit into systemic circulation ( Figure E1 ). After 2 hours, the IVLP perfusate (Steen solution) was exchanged for fresh Steen solution. After 4 hours of IVLP perfusion, the left lung was reperfused via the systemic circulation, and the IVLP cannulas were removed. Right pulmonary vein-and left pulmonary vein-specific arterial blood gas values were measured hourly to assess the performance of each lung independently. Over the final 4 hours of in vivo reperfusion, attempts were made to wean the animal from ECMO support, and if successful, the animal was decannulated from central veno-arterial ECMO. At the end of the experiment, tissue and blood samples were collected, and the animal was euthanized.
Histopathology
From the left lung and right lung, 3 fresh tissue samples (1 upper lobe, 2 lower lobe) were obtained and weighed. A vacuum oven was used to desiccate the tissues at 55 C. Wet-to-dry weight ratios were calculated using separate tissue samples and averaged per lung to assess overall pulmonary edema accumulation.
After fresh tissue samples were obtained, the lungs were fixed via intratracheal instillation of 10% buffered formalin and then stored submerged overnight at 4 C. Following overnight fixation, peripheral lung tissue samples (4 per lung) were obtained, embedded in paraffin, and sectioned. One slide per sample was stained with hematoxylin and eosin. A masked pathologist assessed the hematoxylin and eosin-stained slides for the presence of lung injury. Each slide was scored on a standard scale based on infiltration of polymorphonuclear cells per 403 high-power field (0-3), alveolar edema (0-3), and interstitial inflammation (0-3), as described previously.
23,24
Expression of Biomarkers of Injury and Inflammation
Fresh tissue samples were flash-frozen in liquid nitrogen and stored at À80 C. After homogenization using a FastPrep-24 instrument with Lysing Matrix D tubes (MP Biomedicals, Santa Ana, Calif), the total protein concentration in the supernatant was determined with the bicinchoninic acid protein assay (Pierce, Rockford, Ill). Bronchoalveolar lavage (BAL) of the upper lobe of the lung was also performed, and the BAL fluid obtained was centrifuged and stored at À80
C. In addition, isolated left lung perfusate samples were collected 2 hours after the initiation of IVLP, centrifuged, and stored at À80 C. A multiplex enzyme-linked immunosorbent assay (EMD Millipore, Billerica, Mass) was used to measure cytokine levels in homogenized tissue supernatant (normalized to total protein) or BAL fluid.
Expression of vascular cellular adhesion molecule 1 (VCAM-1) and intracellular adhesion molecule 1 (ICAM-1) in lung tissue was assessed by Western blot analysis. For this analysis, 15 mg of whole-cell protein extract was electrophoresed in a 12% Bis-Tris polyacrylamide gel, then transferred to a nitrocellulose membrane. The membranes were blocked in Tris-buffered saline for 1 hour and in Tween 20 with 5% nonfat milk for 1 hour. After blocking, membranes were incubated with anti-VCAM-1 monoclonal antibody (1:1000; Abcam, Cambridge, United Kingdom) or anti-ICAM-1 monoclonal antibody (1:1000; Abcam) overnight. After 3 washes, membranes were then incubated in horseradish peroxidase-conjugated secondary antibody, followed by another series of washes. Protein was visualized by autoradiography and then analyzed using Image Analysis software (Bio-Rad, Hercules, Calif). Densities were standardized against b-actin levels for each sample.
Statistical Analysis
The Wilcoxon signed-rank paired test for nonparametric data was used to determine statistical significance. To account for repeated measures, a mixed-effects linear regression model with repeated measures was fit. Prism 7 (GraphPad Software, La Jolla, Calif) and SAS version 9.4 (SAS Institute, Cary, NC) were used to perform statistical calculations. All data are reported as mean AE standard deviation. A P value<.05 was considered to indicate statistical significance.
RESULTS
In Vivo Lung Perfusion Model
A total of 8 adult swine underwent the experimental protocol, with significant acute lung injury after infusion of LPS (P/F ratio, 469.0 AE 60.1 initially vs 222.2 AE 60.62 at 2 hours after LPS infusion; P <.008) (Figure 2 ). Of note, there was no difference in oxygenation performance between the right lung and left lung of each animal at baseline and at 2 hours postinjury ( Figure E2 ). All animals were placed on ECMO for respiratory and circulatory support. After isolation of the left pulmonary vasculature, all Figure E3, D) . Furthermore, after 4 hours of reperfusion, 6 of the 8 animals (75%) showed adequate improvement in respiratory status to allow successful ECMO decannulation. In addition, total lung compliance improved significantly from postinjury to postreperfusion (mean, 22.9 AE 6.3 mL/cmH 2 O vs 27.1 AE 4.7 mL/cmH 2 O; P ¼ .008) (Figure 2 and Figure E2, C) . Finally, our mixed-effects linear regression model yielded a mean parameter estimate of þ73.9 AE 18.9 mm Hg for IVLP treatment (P <.0001).
Histopathology
Measurement of lung wet weight-to-dry weight ratios after reperfusion demonstrated significantly reduced edema in the left lungs compared with the right lungs (mean, 6.5 AE 0.8 vs 7.5 AE 1.1; P ¼ .039) (Figure 3) . Furthermore, lung histology was noticeably improved and lung injury severity scores were significantly reduced in the left lungs compared with the right lungs (mean, 1.1 AE 0.5 vs 2.8 AE 1.1; P ¼ .008) (Figure 4 ).
Inflammatory Biomarker Analysis
Expression of the proinflammatory cytokine tumor necrosis factor (TNF)-a was significantly attenuated in the left lung compared with the right lung in both lung tissue homogenate (mean, 0.164 AE 0.12 pg/mL in left lung vs 0.163 AE 0.14 pg/mL in right lung; P ¼ .039) and BAL fluid (mean, 0.081 AE 0.04 pg/mL in left lung vs 0.165 AE 0.10 pg/ mL in right lung; P ¼ .078) ( Figure 5, A and B) . In addition, expression of the proinflammatory cytokine interferon (IFN)-g was significantly lower in both lung tissue homogenate and BAL from the treated left lung compared with the control right lung (lung tissue, mean 0.093 AE 0.02 pg/mL in left lung vs 0.130 AE 0.03 pg/mL in right lung, P ¼ .046; BAL fluid, mean 0.104 AE 0.02 pg/mL in left lung vs 0.138 AE 0.04 pg/mL in right lung, P ¼ .078) ( Figure 5, A  and B) . Expression of the anti-inflammatory cytokine interleukin (IL)-4 was significantly elevated in the left lungs compared with the right lungs (in lung tissue, mean 1.649 AE 0.48 pg/mL in left lung vs 1.138 AE 0.37 pg/mL in right lung, P ¼ .039; in BAL fluid, mean 1.219 AE 0.59 pg/mL in left lung vs 0.625 AE 0.45 pg/mL in right lung, P ¼ .016) (Figure 6 ).
Western blot analysis demonstrated a significantly decreased expression ratio of VCAM-1 in the left lungs compared with the right lungs (mean, 0.201 AE 0.10 vs 0.117 AE 0.12; P ¼ .0391) (Figure 7, A) . Similarly, the ICAM-1 expression ratio was lower in the left lungs, although the difference did not reach statistical significance (mean, 0.377 AE 0.08 vs 0.297 AE 0.16; P ¼ .156) (Figure 7, B) . 
DISCUSSION
In the present study, IVLP of the left lung resulted in significant rehabilitation of sepsis-induced ARDS over a 10-hour period in a preclinical porcine model. Both lungspecific oxygenation and total lung compliance improved after IVLP therapy, with 75% of the animals no longer requiring ECMO support. The mechanism responsible for this improved lung function was likely multifactorial, including reduction of pulmonary edema and attenuation of the inflammatory pathways in the treated lung. These data indicate that IVLP therapy with Steen solution reduces the expression of proinflammatory cytokines TNF-a and INF-g while increasing expression of the antiinflammatory cytokine IL-4. These results correlate with reduced expression of adhesion molecules VCAM-1 and ICAM-1, critical mediators of leukocyte transmigration into lung tissue, after IVLP treatment. This proof-ofconcept study can serve as a launching pad for a novel advanced and rapid surgical approach to treating ARDS, which will require conversion into a percutaneous platform for translation to clinical use.
Steen solution was first described by Steen and colleagues 25 in 2001 as a physiological acellular perfusate consisting of albumin, dextran, and electrolytes, and was subsequently modified by a Toronto group for use in EVLP and lung transplantation. 12, 26 Several groups have demonstrated that perfusion with Steen solution can reduce pulmonary edema in ex vivo perfused lungs. 23, 27, 28 Our LPS-induced model of porcine ARDS simulates the increased vascular permeability observed during sepsis. This injury was ameliorated by 4 hours of IVLP perfusion, and our data demonstrate enduring edema reduction even after 4 hours of reperfusion. In this preclinical model, reduced pulmonary edema is a critical mechanism in improved lung function after IVLP therapy.
Sepsis-induced lung injury through the LPS pathway stimulates an inflammatory cascade through activation of Toll-like receptor 4 (TLR-4), leading to activation of neutrophils and macrophages. 29 Both TNF-a and INF-g are proinflammatory cytokines within this pathway that help amplify the inflammatory response. After 4 hours of IVLP treatment, reduced expression of these cytokines was found in the rehabilitated left lungs compared with the right control lungs despite 4 additional hours of reperfusion. IL-4, a potent immunomodulatory cytokine synthesized and released by Th2 lymphocytes, is known to suppress LPSinduced COX-2 expression in monocytes 30, 31 and also to suppress proinflammatory cytokine production. 32 Wehrmann and colleagues 33 recently suggested that IL-4 expression decreases TNF-a production by resident alveolar macrophages, thereby reducing accumulation of M1 macrophages, inflammation, and alveolar-capillary leak. This anti-inflammatory pathway represents another potential mechanism by which IVLP rehabilitates sepsis-induced lung injury via induction of pathways that mediate resolution of injury.
The pathophysiology of sepsis is associated with an aberrant interaction between leukocytes and vascular endothelium involving the up-regulation of expression of cell adhesion molecules, including VCAM-1 and ICAM-1. 34 Endothelial adhesion molecules play critical roles in LPS-induced lung injury, allowing transmigration of inflammatory cells. 35 This up-regulation of adhesion molecules attracts neutrophils and lymphocytes, further amplifying the inflammatory cascade through release of additional chemoattractants. Thus, we measured the protein expression of VCAM-1 and ICAM-1 in lung tissue as a further indicator of vascular inflammation. In this study, IVLP-treated lungs exhibited significantly reduced VCAM-1 expression compared with untreated lungs, suggesting another mechanism by which IVLP attenuates acute lung injury in this porcine model of sepsis.
Limitations of this study include the complexity of this large animal model, resulting in some variation between animals; however, our comparison of results in the left and right lungs of the same animal minimizes this effect. Nonetheless, although this validated porcine model of sepsisinduced acute lung injury demonstrates a reproducible reduction in lung compliance and oxygenation, it does not directly translate to the chronic nature of sepsis in a critically ill patient with severe ARDS necessitating ECMO. Additional mechanistic studies are needed to discover specific signaling pathways that are affected by IVLP, with Steen solution providing attenuation of lung injury. Finally, translation into human studies will require an entirely percutaneous approach to IVLP, which hopefully will ultimately lead to the transformation of ARDS from a longterm condition with high morbidity and mortality to a treatable illness with shorter recovery, lower healthcare-related costs, and increased survival.
In conclusion, 4 hours of IVLP significantly rehabilitated LPS-induced lung injury and attenuated the need for ECMO support in 75% of animals. Lung injury is ameliorated by IVLP through several mechanisms involving reduced lung edema, reduced proinflammatory cytokine and adhesion molecule levels, and increased anti-inflammatory cytokine levels. In the near future, when translated into a percutaneous platform, IVLP may provide a reliable means to rehabilitate various types of acute lung injury in patients on ECMO, leading to reduced morbidity and mortality in patients with ARDS.
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